Sun Pharmaceutical Industries Limited announced that the US Food and Drug Administration (US FDA) conducted an inspection at the Company’s Baska facility from 8 September 2025 to 19 September 2025. The US FDA has subsequently determined that the inspection classification status of this facility is Official Action Indicated (OAI). The company stated that it continues to manufacture and supply approved products from the facility to the US market and will work with the regulator to achieve fully compliant status.
